Invert

Executive Summary

Invert is a San Francisco-based bioprocess AI software company founded in 2020 that addresses a critical pain point in the biomanufacturing industry: fragmented and siloed bioprocess data. By providing a purpose-built platform that connects, structures, and analyzes data from bioreactors and instruments, Invert enables biotech teams to gain real-time insights and leverage AI-driven decisions to streamline development and manufacturing workflows. The company operates at the intersection of AI/ML and drug delivery, targeting a market where data integration and analytics can significantly reduce costs and time-to-market for biologics. As a private, early-stage company, Invert has yet to disclose funding or valuation, but its focus on a high-impact niche positions it for growth as the biopharma industry increasingly adopts digital transformation.

Upcoming Catalysts (preview)

• Q2 2026Series A funding announcement70% success
• H2 2026Partnership with a top 20 biopharma company50% success
• Q3 2026Launch of AI predictive analytics module80% success